Table 1.

Patient and clinical characteristics

Arm AArm B/C
(N = 419)(N = 906)P
Age0.75
N419906
 Mean (SD)50.0 (10.0)50.2 (10.3)
 Median5050
 Q1, Q343.0, 57.043.0, 57.0
 Range(27.0–80.0)(22.0–82.0)
Age group0.82
 <4062 (15%)147 (16%)
 40–49140 (33%)278 (31%)
 50–59145 (35%)316 (35%)
 ≥6072 (17%)165 (18%)
Menopausal status0.68
 Premenopausal or <50223 (53%)471 (52%)
 Postmenopausal or ≥50196 (47%)435 (48%)
Breast surgery0.5
 Breast sparing177 (42%)365 (40%)
 Mastectomy242 (58%)541 (60%)
Positive nodes0.99
 Axdis 1–3 positive164 (39%)348 (38%)
 Axdis 4–9 positive107 (26%)246 (27%)
 Axdis 10+ positive47 (11%)99 (11%)
 Positive sent node35 (8%)80 (9%)
 Negative sent node40 (10%)82 (9%)
 Negative axdis26 (6%)51 (6%)
Receptor status0.4
 ER-positive and/or PR-positive226 (54%)511 (56%)
 Other193 (46%)395 (44%)
Tumor size, cm0.61
 ≤2.0170 (41%)394 (43%)
 2.0–5.0 cm218 (52%)447 (49%)
 >5.0 cm31 (7%)65 (7%)
Histology0.23
 Ductal390 (93%)860 (95%)
 Other28 (7%)46 (5%)
 Missing10
Tumor grade0.61
 High301 (73%)644 (72%)
 Low/intermediate111 (27%)254 (28%)
 Missing78
Tumor stage0.61
 1170 (41%)394 (43%)
 2218 (52%)447 (49%)
 331 (7%)65 (7%)
N stage0.34
 066 (16%)133 (15%)
 1334 (80%)722 (80%)
 218 (4%)51 (6%)
 31 (0%)0 (0%)
Agent0.52
 None193 (46%)396 (44%)
 Other77 (18%)158 (17%)
 Tamoxifen149 (36%)352 (39%)

Abbreviations: Axdis, axillary lymph node dissection; ER, estrogen receptor; positive sent, positive sentinel node dissection; negative sent, negative sentinel node dissection; negative axdis, negative axillary node; PR, progesterone receptor.